Clinical Trial

EGEN-5784 Porcine Liver With the Metra® ELC Device

Not Yet Recruiting Phase 1

Summary

This is a Phase 1, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC device are designed to support liver function during the treatment period

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-17.

Trial Details

NCT Number	NCT07429838
Lead Sponsor	eGenesis, INC Collaborators: OrganOx Ltd.
Conditions	Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
Enrollment	20 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-07